638217-49-9

Basic information

• Product Name: benzyl (3R)-3-[(tert-butoxycarbonyl)(methyl)amino]pyrrolidine-1-carboxylate
• Synonyms: benzyl (3R)-3-[(tert-butoxycarbonyl)(methyl)amino]pyrrolidine-1-carboxylate
• CAS NO: 638217-49-9
• Molecular Formula: C18H26N2O4
• Molecular Weight: 334.415
• Mol File: 638217-49-9.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: benzyl (3R)-3-[(tert-butoxycarbonyl)(methyl)amino]pyrrolidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: benzyl (3R)-3-[(tert-butoxycarbonyl)(methyl)amino]pyrrolidine-1-carboxylate(638217-49-9)
• EPA Substance Registry System: benzyl (3R)-3-[(tert-butoxycarbonyl)(methyl)amino]pyrrolidine-1-carboxylate(638217-49-9)

Safety Data

• Hazardous Substances Data: 638217-49-9(Hazardous Substances Data)

Upstream product

• 122536-75-8 Benzyl (3R)-3-[(tert-butoxycarbonyl)amino]pyrrolidine-1-carboxylate 
• 74-88-4 methyl iodide 

Downstream Products

• 917357-84-7 benzyl (3R)-3-[(2-ethoxy-2-oxo-ethyl)(methyl)amino]pyrrolidine-1-carboxylate 
• 917357-85-8 benzyl (3R)-3-[(2-hydroxyethyl)(methyl)amino]pyrrolidine-1-carboxylate 
• 917357-86-9 2-{methyl[(3R)-pyrrolidin-3-yl]amino}ethanol 
• 392338-15-7 tert-butyl [(3R)-pyrrolidin-3-yl]methylcarbamate 
• 917357-83-6 benzyl (3R)-3-(methylamino)-pyrrolidine-1-carboxylate hydrochloride 

Relevant articles and documents

4, 6-DISUBSTITUTED 2-AMINO-PYRIMIDINES AS HISTAMINE H4 RECEPTOR MODULATORS

The present invention relates to substituted heterocyclic compounds of Formula (I) or pharmaceutically acceptable salts or N-oxides or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are histamine H4 receptor inhibitors/antagonists useful in the treatment of histamine H4 receptor-associated conditions or diseases or disorders including, for example, inflammatory diseases or disorders, pruritus, and pain.

INHIBITORS OF 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE 1

The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salts or solvates thereof, wherein n, X, Y, R1, R2, R3 and R4 are as described in the specification. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating conditions that are mediated by the modulation of 11 βHSD1 , the method comprising administering to a mammal an effective amount of a compound of formula (I).